The oncogenic potentials and diagnostic significance of long non‐coding RNA LINC00310 in breast cancer

Abstract

Recent studies have revealed that long non‐coding RNAs (lncRNAs) are involved in different physiological processes and human diseases. However, to date, the function and overall clinical significance of the vast majority of lncRNAs in breast cancer remain largely unexplored. Here, we focused on LINC00310 by interrogating the breast invasive carcinoma data set of the Cancer Genome Atlas (TCGA). The results showed that LINC00310 was increased as breast cancer progressed, and the deregulation of LINC00310 was significantly associated with patients’ survival. Experiments with knockout (KO) approach by CRISPR/Cas9 system and the subsequent rescue experiments revealed that LINC00310 promoted cell proliferation by regulating c‐Myc expression in vitro. Nude mouse xenograft assay demonstrated that LINC00310 KO significantly suppressed tumour growth in vivo. Furthermore, we found that serum LINC00310 expression was significantly up‐regulated in patients with breast cancer, and receiver operating characteristic (ROC) curve analysis indicated that LINC00310 had a powerful capability of distinguishing patients with breast cancer from healthy individuals (the area under curve 0.828). Taken together, these results provide a more intuitive approach to explore the clinical relevance and functional roles of lncRNAs. As a result, lncRNAs, such as LINC00310, may be used in clinical applications as circulating markers for breast cancer.

lncRNA Profiles Enable Prognosis Prediction and Subtyping for Esophageal Squamous Cell Carcinoma

“…In recent years, more and more novel lncRNAs have been identified and the roles of lncRNAs in cancer development have been increasingly studied ( Yang et al, 2014 ; Bhan et al, 2017 ; Peng et al, 2017 ). In our previous study, we have shown the effectiveness of lncRNA signatures in diagnosis, prognostic prediction, and drug-resistance in four common cancers, namely breast cancer, colorectal cancer, bladder cancer, and lung cancer ( Li et al, 2017 , 2018a ; Xie et al, 2018 ; Zhan et al, 2018 ; Zhang et al, 2019 ). Here, we identified an 11-lncRNA model that was associated with tumor OS in ESCC patients, constructed a lncRNA-based molecular subtype of ESCC, and found that lncRNA AC007128.1 might mediate ESCC EMT through mitogen-activated protein kinases/extracellular signal-regulated kinase (MAPK/ERK) and MAPK/p38 signaling pathways.…”

“…Our previous study has shown that the serumal and/or urinary exosome lncRNA profiles can be applied to the diagnosis and prognostic prediction of bladder cancer, colorectal cancer, breast cancer, and lung cancer ( Li et al, 2017 , 2018a ; Xie et al, 2018 ; Zhan et al, 2018 ; Zhang et al, 2019 ). In the present study, we used publicly available The Cancer Genome Atlas (TCGA) RNA-seq expression data and evaluated the potential effectiveness of lncRNA biomarkers for prognosis and subtyping of ESCC.…”

Comprehensive analysis of competing endogenous RNA network and 3-mRNA signature predicting survival in papillary renal cell cancer

“…[30] LINC00310 was elucidated to promote cell proliferation by regulating c-Myc expression and serum LINC00310 expression exerted diagnostic significance in breast cancer. [31] LINC00462 promotes hepatocellular carcinoma progression through the PI3K/AKT signaling pathway. [32] In addition, LINC00462 also act as a target of miR-665 and activate the SMAD2/3 pathway by enhancing the expression levels of TGFBR1 and TGFBR2, and promote tumorigenesis in pancreatic cancer.…”

Circulating Serum Exosomal Long Non-Coding RNAs FOXD2-AS1, NRIR, and XLOC_009459 as Diagnostic Biomarkers for Colorectal Cancer

“…More importantly, lncRNAs seem to be measurable in body fluids, including the plasma, serum, and urine, empowering their potential as the non-invasive biomarkers for diagnostics of malignancies. For example, lncRNA XLOC_009167 can serve as a novel diagnostic biomarker for distinguishing lung cancer from benign lung disease and healthy controls (14); LINC00310, upregulated in breast tumors, is detected in the serum of breast cancer patients and serves as a promising diagnostic biomarker (15).…”